# Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

> **NCT04740307** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 116 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab/Quavonlimab
- **DRUG:** Lenvatinib
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04740307
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-16
- **Primary completion:** 2025-07-29
- **Final completion:** 2025-07-29
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04740307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04740307, "Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04740307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*